Irinotecan for relapsed Wilms tumor in pediatric patients: SIOP experience and review of the literature—A report from the SIOP Renal Tumor Study Group

Janna A. Hol, Marry M. van den Heuvel-Eibrink, Norbert Graf, Kathy Pritchard-Jones, Jesper Brok, Harm van Tinteren, Lisa Howell, Arnauld Verschuur, Christophe Bergeron, Leo Kager, Serena Catania, Filippo Spreafico, Annelies M.C. Mavinkurve-Groothuis

Research output: Contribution to journalArticlepeer-review

Abstract

While irinotecan has been studied in various pediatric solid tumors, its potential role in Wilms tumor (WT) is less clear. We evaluated response and outcome of irinotecan-containing regimens in relapsed WT and compared our results to the available literature. Among 14 evaluable patients, one complete response (CR) and two partial responses (PRs) were observed in patients with initial intermediate-risk (CR and PR) and blastemal-type histologies (PR). Two patients were alive at last follow-up showing no evidence of disease. Our results and the reviewed literature suggest some effectiveness of irinotecan in the setting of relapsed WT.

Original languageEnglish
Article numbere26849
JournalPediatric Blood and Cancer
Volume65
Issue number2
DOIs
Publication statusPublished - Feb 1 2018

Keywords

  • irinotecan
  • pediatric solid tumors
  • relapsed Wilms tumor

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Irinotecan for relapsed Wilms tumor in pediatric patients: SIOP experience and review of the literature—A report from the SIOP Renal Tumor Study Group'. Together they form a unique fingerprint.

Cite this